Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.57
OMER's Cash-to-Debt is ranked lower than
86% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OMER: 0.57 )
Ranked among companies with meaningful Cash-to-Debt only.
OMER' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.16 Max: 23.84
Current: 0.57
0.21
23.84
Equity-to-Asset -0.56
OMER's Equity-to-Asset is ranked lower than
96% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMER: -0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
OMER' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.21  Med: -0.55 Max: 0.7
Current: -0.56
-4.21
0.7
Piotroski F-Score: 4
Altman Z-Score: -7.47
Beneish M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -130.42
OMER's Operating Margin % is ranked lower than
54% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. OMER: -130.42 )
Ranked among companies with meaningful Operating Margin % only.
OMER' s Operating Margin % Range Over the Past 10 Years
Min: -12988.5  Med: -1349.45 Max: -130.42
Current: -130.42
-12988.5
-130.42
Net Margin % -160.38
OMER's Net Margin % is ranked lower than
58% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. OMER: -160.38 )
Ranked among companies with meaningful Net Margin % only.
OMER' s Net Margin % Range Over the Past 10 Years
Min: -13668.46  Med: -1295.19 Max: -160.38
Current: -160.38
-13668.46
-160.38
ROA % -123.09
OMER's ROA % is ranked lower than
89% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OMER: -123.09 )
Ranked among companies with meaningful ROA % only.
OMER' s ROA % Range Over the Past 10 Years
Min: -538.37  Med: -106.19 Max: -50.37
Current: -123.09
-538.37
-50.37
ROC (Joel Greenblatt) % -5369.60
OMER's ROC (Joel Greenblatt) % is ranked lower than
82% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OMER: -5369.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMER' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8254.24  Med: -3348.17 Max: -2046.97
Current: -5369.6
-8254.24
-2046.97
3-Year Revenue Growth Rate 163.90
OMER's 3-Year Revenue Growth Rate is ranked higher than
96% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. OMER: 163.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMER' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -17 Max: 163.9
Current: 163.9
0
163.9
3-Year EBITDA Growth Rate 3.70
OMER's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OMER: 3.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMER' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.7 Max: 21.2
Current: 3.7
0
21.2
3-Year EPS without NRI Growth Rate 5.90
OMER's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OMER: 5.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMER' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.5 Max: 19.8
Current: 5.9
0
19.8
GuruFocus has detected 5 Warning Signs with Omeros Corp $OMER.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OMER Guru Trades in Q3 2015

Paul Tudor Jones 13,000 sh (New)
Jim Simons 12,593 sh (-90.76%)
» More
Q4 2015

OMER Guru Trades in Q4 2015

Joel Greenblatt 10,225 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2016

OMER Guru Trades in Q1 2016

Joel Greenblatt 19,241 sh (+88.18%)
» More
Q2 2016

OMER Guru Trades in Q2 2016

Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NDRM, NAS:NLNK, OTCPK:PHMMF, NAS:ITCI, NAS:JNCE, NYSE:MYOV, NAS:IMMU, OTCPK:MEOBF, NAS:BCRX, NAS:ADRO, OTCPK:IPHYF, NAS:INSY, NAS:KERX, NAS:PGNX, NAS:TGTX, NAS:VSAR, NAS:MGNX, NAS:WVE, NAS:ANIK, OTCPK:GNIIF » details
Traded in other countries:3O8.Germany,
Headquarter Location:USA
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corp is a U.S.-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Ratios

vs
industry
vs
history
PS Ratio 15.79
OMER's PS Ratio is ranked lower than
54% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. OMER: 15.79 )
Ranked among companies with meaningful PS Ratio only.
OMER' s PS Ratio Range Over the Past 10 Years
Min: 8.14  Med: 36.43 Max: 1667.33
Current: 15.79
8.14
1667.33
EV-to-EBIT -12.15
OMER's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. OMER: -12.15 )
Ranked among companies with meaningful EV-to-EBIT only.
OMER' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.9  Med: -6.5 Max: 0.3
Current: -12.15
-14.9
0.3
EV-to-EBITDA -12.24
OMER's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. OMER: -12.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMER' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15  Med: -6.5 Max: 0.3
Current: -12.24
-15
0.3
Current Ratio 3.75
OMER's Current Ratio is ranked lower than
53% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. OMER: 3.75 )
Ranked among companies with meaningful Current Ratio only.
OMER' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.53 Max: 5.47
Current: 3.75
0.49
5.47
Quick Ratio 3.68
OMER's Quick Ratio is ranked lower than
51% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OMER: 3.68 )
Ranked among companies with meaningful Quick Ratio only.
OMER' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.51 Max: 5.47
Current: 3.68
0.46
5.47
Days Inventory 348.87
OMER's Days Inventory is ranked lower than
87% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. OMER: 348.87 )
Ranked among companies with meaningful Days Inventory only.
OMER' s Days Inventory Range Over the Past 10 Years
Min: 182.32  Med: 194.56 Max: 348.87
Current: 348.87
182.32
348.87
Days Sales Outstanding 104.69
OMER's Days Sales Outstanding is ranked lower than
73% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. OMER: 104.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMER' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.06  Med: 95.58 Max: 265.45
Current: 104.69
36.06
265.45
Days Payable 651.16
OMER's Days Payable is ranked higher than
97% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. OMER: 651.16 )
Ranked among companies with meaningful Days Payable only.
OMER' s Days Payable Range Over the Past 10 Years
Min: 651.16  Med: 1452.49 Max: 2253.81
Current: 651.16
651.16
2253.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.00
OMER's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. OMER: -13.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMER' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -98.1  Med: -13 Max: 0
Current: -13
-98.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.43
OMER's Price-to-Median-PS-Value is ranked higher than
83% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OMER: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMER' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.88 Max: 45.05
Current: 0.43
0.26
45.05
Earnings Yield (Greenblatt) % -8.23
OMER's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. OMER: -8.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMER' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.49  Med: 381.25 Max: 1464.3
Current: -8.23
-8.49
1464.3

More Statistics

Revenue (TTM) (Mil) $41.62
EPS (TTM) $ -1.66
Beta4.05
Short Percentage of Float20.61%
52-Week Range $7.20 - 17.19
Shares Outstanding (Mil)43.82

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 67 139 218
EPS ($) -1.25 -0.04 0.97
EPS without NRI ($) -1.25 -0.04 0.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OMER

Headlines

Articles On GuruFocus.com
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 

More From Other Websites
Biotech Movers: OncoMed, Incyte, Omeros Apr 17 2017
3 Biotech Stocks to Buy on Sale Apr 15 2017
Omeros to Present at the Needham Healthcare Conference Apr 03 2017
Biotech Premarket Movers: Halozyme, Omeros, Aralez Mar 30 2017
Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases Mar 30 2017
ETFs with exposure to Omeros Corp. : March 30, 2017 Mar 29 2017
Top Biotech Stocks for Growth Investors Mar 29 2017
Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its... Mar 29 2017
Here's Why Omeros Corporation Stock Climbed Higher Today Mar 28 2017
3 Stocks That Could Make You Rich Mar 28 2017
Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and... Mar 28 2017
Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic... Mar 27 2017
Omeros: Power in the Pipeline Mar 24 2017
Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Mar 21 2017
Omeros Corp. :OMER-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
3 Beaten-Up Biotech Stocks: Are They Bargains? Mar 21 2017
Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : March 20, 2017 Mar 20 2017
Edited Transcript of OMER earnings conference call or presentation 16-Mar-17 8:30pm GMT Mar 17 2017
Omeros reports 4Q loss Mar 16 2017
Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results Mar 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)